A Feasibility Study of Novel Ultrasonic Tissue Characterization for Prostate-cancer Diagnosis: 2D Spectrum Analysis of in Vivo Data with Histology As Gold Standard
Overview
Authors
Affiliations
This study demonstrates the feasibility of using a novel 2D spectrum ultrasonic tissue characterization (UTC) technique for prostate-cancer diagnosis. Normalized 2D spectra are computed by performing Fourier transforms along the range (beam) and the cross-range directions of the digital radio-frequency echo data, then dividing by a reference spectrum. This 2D spectrum method provides axial and lateral information of tissue microstructures, an improvement over the current 1D spectrum analysis which only provides axial information. A pilot study was conducted on four prostate-cancer patients who underwent radical prostatectomies. Cancerous and noncancerous regions of interest, identified through histology, were compared using four 2D spectral parameters: peak value and 3 dB width of the radially integrated spectral power (RISP), slope and intercept of the angularly integrated spectral power (AISP). For noncancerous and cancerous prostatic tissues, respectively, our investigation yielded 23 +/- 1 and 26 +/- 1 dB for peak value of RISP, 7.8 +/- 0.5 degrees and 7.6 +/- 0.6 degrees for 3 dB of RISP, -2.1 +/- 0.2 and -2.7 +/- 0.4 dB/MHz for slope of AISP, and 92 +/- 5 and 112 +/- 6 dB for intercept of AISP. Preliminary results indicated that 2D spectral UTC has the potential for identifying tumor-bearing regions within the prostate gland.
Klingensmith J, Haggard A, Ralston J, Qiang B, Fedewa R, Elsharkawy H J Med Imaging (Bellingham). 2019; 6(4):047001.
PMID: 31720315 PMC: 6835052. DOI: 10.1117/1.JMI.6.4.047001.
Li F, Huang Y, Wang J, Lin C, Li Q, Zheng X Cancer Imaging. 2019; 19(1):61.
PMID: 31462322 PMC: 6714306. DOI: 10.1186/s40644-019-0248-y.
Ultrasonic RF time series for early assessment of the tumor response to chemotherapy.
Lin Q, Wang J, Li Q, Lin C, Guo Z, Zheng W Oncotarget. 2018; 9(2):2668-2677.
PMID: 29416800 PMC: 5788668. DOI: 10.18632/oncotarget.23625.
Lin C, Cao L, Wang J, Zheng W, Chen Y, Feng Z BMC Cancer. 2013; 13:302.
PMID: 23800247 PMC: 3698196. DOI: 10.1186/1471-2407-13-302.